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New WHO recommendations to improve the outcomes of 
preterm birth
An estimated 15 million babies are born preterm 
annually.1 Preterm birth complications account for more 
than 15% of deaths in children younger than 5 years2 
and survivors often have long-term consequences 
with respect to their health, growth, and psychosocial 
functioning.3,4 The most beneﬁ cial interventions 
available are those that improve newborn outcomes 
when preterm birth is inevitable (tertiary interventions) 
and those that focus on special care for preterm 
newborns. Today WHO publishes new recommendations 
on interventions for pregnant women in whom preterm 
birth is imminent (including antenatal corticosteroids, 
tocolytics, magnesium sulfate, antibiotics, and mode 
of delivery) and for care of preterm neonates (including 
thermal care, continuous positive airway pressure 
[CPAP], surfactant administration, and oxygen therapy) 
to improve preterm birth outcomes.5
Although there is strong evidence of beneﬁ t from 
trials after administration of antenatal corticosteroids, 
most of these were conducted in high-income 
countries, in higher-level facilities where the 
accuracy of gestational age estimation was high, and 
comprehensive maternal and newborn care was likely 
to be available. The recent Antenatal Corticosteroids 
Trial6 has raised concerns about extending antenatal 
corticosteroid use to peripheral levels of the health 
system in lower-income countries. The WHO Guideline 
Development Group therefore took a cautious approach, 
recommending that certain preconditions are met 
before antenatal corticosteroid administration, on the 
basis of the context of the existing trials. The guidelines 
therefore recommend antenatal corticosteroid therapy 
for women at risk of preterm birth from 24 weeks to 
34 weeks of gestation when the following conditions 
are met: (1) gestational age can be accurately assessed, 
(2) preterm birth is considered imminent, (3) there is 
no clinical evidence of maternal infection, (4) adequate 
childbirth care is available, and (5) the preterm neonate 
can receive adequate care for complications, if needed 
(including resuscitation, thermal care, feeding support, 
infection treatment, and safe oxygen use). 
Accurate and standardised gestational age assessment 
(ideally, by ﬁ rst trimester ultrasonography) is important 
to ensure all eligible mothers receive antenatal 
corticosteroids while avoiding unnecessary treatment for 
those not in the targeted gestational age range. Antenatal 
corticosteroids should not be routinely administered 
in situations where the gestational age cannot be 
conﬁ rmed (particularly when suspected to be more than 
34 weeks) because risks of harm could outweigh beneﬁ ts 
if matured babies are exposed to corticosteroids in utero. 
Nevertheless, it is crucial that every preterm neonate 
receives prompt and comprehensive care to prevent or 
mitigate complications.
The guidelines also recommend antenatal cortico-
steroid use in singleton and multiple pregnancies, 
preterm prelabour rupture of membranes where there 
are no clinical signs of infection, and in women with 
hypertensive disorders, diabetes, and growth-restricted 
fetuses. Although the evidence regarding antenatal 
corticosteroid use and exacerbation of maternal 
infectious morbidity is not entirely conclusive, the 
biological plausibility of such a relation cannot be 
ignored, particularly in settings where appropriate 
supportive care cannot be guaranteed. Antenatal 
corticosteroid use is therefore not recommended for 
women with chorioamnionitis.
WHO acknowledges that it might not be feasible 
to operationalise all preconditions for antenatal 
corticosteroid use in a standard and consistent manner 
across resource-limited settings. Further research on the 
eﬃ  cacy of antenatal corticosteroids in facility settings in 
lower-income countries is urgently needed to identify 
the most essential (or minimum) preconditions to safely 
achieve clinical beneﬁ ts from antenatal corticosteroids. 
Existing trials have shown that tocolytics can delay 
preterm birth by 2–7 days; however, there is limited 
evidence that they aﬀ ect substantive perinatal outcomes, 
and they could have adverse eﬀ ects on the mother.5 
Consequently, the guidelines do not recommend their 
use for the purpose of improving newborn outcomes. 
If tocolytics are used (ie, to facilitate antenatal 
corticosteroid administration or in-utero fetal transfer to 
a special care setting), nifedipine is the preferred agent. 
WHO considers studies on tocolytics for improving critical 
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Preterm babies are at risk of respiratory complications, 
and commonly have diﬃ  culties in feeding and in 
main taining temperature. Kangaroo mother care—a 
relatively low-cost intervention—is recommended for 
the routine care of babies weighing 2000 g or less in 
health facilities, as soon as they are clinically stable. 
Key features include early, continuous, and prolonged 
skin-to-skin contact between mother and baby, as 
well as exclusive breastfeeding or breastmilk feeding. 
It is recommended that kangaroo mother care be 
as continuous as possible. Although this might be 
challenging, even intermittent kangaroo mother care 
is beneﬁ cial and preferred to conventional thermal care. 
Preterm babies who are not eligible or cannot receive 
kangaroo mother care should be cared for in a thermo-
neutral environment under radiant warmers or in 
incubators. There is insuﬃ  cient evidence to recommend 
the use of plastic bags or wraps for routine thermal 
care; however, they could be beneﬁ cial in preventing 
hypothermia during stabilisation or transfer of the 
neonate to specialised neonatal care units.
CPAP, and in appropriate settings surfactant 
replacement therapy, is recommended for preterm 
neonates diagnosed with respiratory distress syndrome 
and they should be initiated as soon as the diagnosis is 
made. Surfactant replacement therapy should only be 
administered in facilities where intubation, ventilator 
care, blood gas analysis, newborn nursing care, and 
monitoring are available. Prophylactic use of surfactants 
is not recommended. 
Appropriate oxygen therapy is crucial when preterm 
neonates require ventilation for resuscitation 
immediately after birth. Recognising the harms of 
using high concentrations of oxygen in preterm babies 
younger than 32 weeks’ gestation, the guidelines 
recommend that ventilation should be initiated with 
30% oxygen, and carefully increased only if bradycardia 
continues or targeted oxygen saturation concentrations 
are not reached despite adequate ventilation. 100% 
oxygen should never be used—resuscitation with room 
air should be done if blending air–oxygen is impossible.
WHO acknowledges that improving the outcomes of 
preterm neonates remains a challenging task. Health 
providers and health systems need to be equipped to 
reliably assess gestational age, recognise the signs of 
preterm labour, provide prompt and eﬀ ective newborn 
care, and use interventions safely and appropriately 
while minimising harm. The recommendations 
highlight key evidence gaps, particularly related to 
the use of antenatal corticosteroids and tocolytics 
in resource-limited settings. Further trials of these 
interventions are urgently required.
*Joshua P Vogel, Olufemi T Oladapo, Alexander Manu, 
A Metin Gülmezoglu, Rajiv Bahl
UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of 
Research, Development and Research Training in Human 
Reproduction, Department of Reproductive Health and Research 
(JPV, OTO, AMG) and Department of Maternal, Newborn, 
Child and Adolescent Health (AM, RB), WHO, 1211 Geneva 27, 
Switzerland
vogeljo@who.int
This guideline was jointly developed by the Department of Maternal, Newborn, 
Child and Adolescent Health and the Department of Reproductive Health and 
Research at the WHO in Geneva, who oversaw systematic searches, synthesis, 
and assessment of the evidence. WHO gratefully acknowledges the 
contributions of the many individuals and organisations to the development of 
this guideline, including systematic reviewers, members of the Guideline 
Development Group, and other collaborators. We thank James Neilson and 
Roger Soll who served as chairs of the entire Guideline Development Group and 
newborn health subgroup of the Guideline Development Group, respectively.
©2015 World Health Organization; licensee Elsevier. This is an Open Access 
article published without any waiver of WHO’s privileges and immunities under 
international law, convention, or agreement. This article should not be 
reproduced for use in association with the promotion of commercial products, 
services or any legal entity. There should be no suggestion that WHO endorses 
any speciﬁ c organisation or products. The use of the WHO logo is not permitted. 
This notice should be preserved along with the article’s original URL. 
1 Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional, and 
worldwide estimates of preterm birth rates in the year 2010 with time 
trends since 1990 for selected countries: a systematic analysis and 
implications. Lancet 2012; 379: 2162–72. 
2 Liu L, Oza S, Hogan D, et al. Global, regional, and national causes of child 
mortality in 2000–13, with projections to inform post-2015 priorities: 
an updated systematic analysis. Lancet 2015; 385: 430–40. 
3 Teune MJ, Bakhuizen S, Bannerman CG. A systematic review of severe 
morbidity in infants born late preterm. Am J Obstet Gynecol 2011; 205: 374. 
4 Moster D, Lie RT, Markestad T. Long-term medical and social consequences 
of preterm birth. N Engl J Med 2008; 359: 262–73. 
5 World Health Organization. WHO recommendations on interventions to 
improve preterm birth outcomes. Geneva: World Health Organization, 
2015. http://www.who.int/reproductivehealth/publications/
maternal_perinatal_health/preterm-birth-guideline.
6 Althabe F, Belizan JM, McClure EM, et al. A population-based, multifaceted 
strategy to implement antenatal corticosteroid treatment versus standard 
care for the reduction of neonatal mortality due to preterm birth in 
low-income and middle-income countries: the ACT cluster-randomised 
trial. Lancet 2015; 385: 629–39.
